| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04777708 Details | 2023-03-24 Interventional | 1 | 1 | Pembrolizumab Carcinoma Carcinoma, Hepa… Advanced Hepato… BCLC Stage B He… BCLC Stage C He… Refractory Hepa… | Withdrawn by sponsor - | |||
| NCT04730349 2020-000854-85 Details | 2023-03-24 Interventional | 1/2 | 15 | Nivolumab Brain Neoplasms Ependymoma Glioma Leukemia Lymphoma Medulloblastoma Neuroblastoma Rhabdomyosarcom… Sarcoma Sarcoma, Ewing Ewing Sarcoma High-grade Glio… Leukemia and Ly… Miscellaneous B… Miscellaneous S… Relapsed, Refra… | Business objectives have changed On 14-Apr-2022, a joint decision was made to end the clinical development program for bempegaldesleukin in combination with nivolumab, resulting in the termination of this study. This results disclosure report provides analyses from CA045-020 Part A safety analyses only. Part B of the study (expansion phase) did not enroll any participants. | |||
| NCT04034225 Details | 2023-03-24 Interventional | 1/2 | 25 | Pembrolizumab Carcinoma Carcinoma, Squa… Squamous Cell C… Squamous Cell C… | Terminated by the sponsor The study stopped prematurely for lack of efficacy 25 patients were enrolled. Lab analyzes were not performed. | |||
| NCT02395848 Details | 2023-03-24 Interventional | 3 | 31 | Fidaxomicin Clostridium Inf… Communicable Di… Infections Clostridium Dif… | Insufficient resource to complete the study - | |||
| NCT03418532 Details | 2023-03-23 Interventional | 1 | 8 | Osimertinib Carcinoma, Non-… EGFR-mutated NS… | Sponsor's decision - | |||
| NCT03417401 Details | 2023-03-23 Interventional | 1 | 0 | Plasminogen Tissue Plasmino… Retinal Vein Oc… Central Retinal… | organizationally not yet possible - | |||
| NCT04903054 Details | 2023-03-22 Interventional | 2 | 0 | Antilymphocyte … Methylprednisol… Mycophenolic Ac… Prednisone Tacrolimus Thymoglobulin Kidney Transpla… Renal Transplan… | Limited period of availability of a supply of the study drug and difficulties in enrollment - | |||
| NCT04252768 Details | 2023-03-22 Interventional | 1 | 0 | Paclitaxel Breast Neoplasm… Metastatic Brea… | Replaced by other study NCT05747794 - | |||
| NCT04840472 Details | 2023-03-21 Interventional | 1 | - | Panitumumab Head and Neck N… Head and Neck C… | Logistics - | |||
| NCT04371107 Details | 2023-03-21 Interventional | 3 | 11 | Azithromycin COVID-19 Ambulatory Azithromycin Covid19 | ANSM notifications - | |||
| NCT04221087 Details | 2023-03-21 Interventional | 4 | 3 | Dexamethasone Bronchiolitis Bronchiolitis, … | COVID19-pandemic, RSV surge - | |||
| NCT03556202 2017-003299-30 Details | 2023-03-21 Interventional | 3 | 1936 | Mirikizumab Psoriasis | The study was terminated due to a strategic business decision made by the Sponsor. This study was terminated before completion of the long-term extension trial, due to strategic business decision made by the company. | |||
| NCT03281304 2017-002274-39 Details | 2023-03-21 Interventional | 4 | 140 | Tofacitinib Colitis Colitis, Ulcera… Ulcer Ulcerative Coli… | The study terminated early due to business reasons, with the study already meeting its primary
objective. The decision to terminate the trial was not based on any safety and/or efficacy
concerns. - | |||
| NCT05252598 Details | 2023-03-20 Interventional | 1 | 0 | Psilocybin Dyssomnias Parasomnias Anxiety Drug Effect Health, Subject… Mood Change Mood Disturbanc… Psilocin Toxici… Psilocybin Caus… Psilocybin Toxi… Psychedelic Exp… Sleep Disturban… | The sponsor no longer wishes to pursue the methods outlined in the protocol. - | |||
| NCT04826016 2020-004203-13 Details | 2023-03-20 Interventional | 1/2 | 0 | Paclitaxel Breast Neoplasm… Advanced Breast… | Funder decision - | |||
| NCT02291055 Details | 2023-03-20 Interventional | 1/2 | [1 Refs] | 75 | Durvalumab Head and Neck N… Cancer Cervical Cancer Head and Neck C… | - Based on a discussion with the FDA, a 1-year duration of the Listeria monocytogenes surveillance period was considered sufficient (instead of protocol specified 3-years period) to monitor and characterize any potential risk associated with delayed listeremia, and therefore, the study was terminated early. | ||
| NCT03621982 2019-003132-23 Details | 2023-03-17 Interventional | 1 | 78 | Pembrolizumab Carcinoma Carcinoma, Rena… Fallopian Tube … Pancreatic Neop… Triple Negative… Advanced Solid … Bladder Cancer Colo-rectal Can… Esophageal Canc… Fallopian Tube … Gastric Cancer Head and Neck C… Melanoma Non-small Cell … Ovarian Cancer Pancreas Cancer Renal Cell Carc… Triple-negative… | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory
activity. However, the signals were insufficiently compelling at the tested dose/schedule to
justify continuation of the study. - | |||
| NCT03315832 Details | 2023-03-17 Interventional | 2/3 | 0 | Valsartan Aortic Valve St… Constriction, P… Hypertrophy Hypertrophy, Le… Angiotensin Rec… Heart Valve Pro… Transcatheter A… Valsartan | problem of faisability - | |||
| NCT05379322 Details | 2023-03-15 Interventional | 3 | 0 | Adalimumab Etanercept Golimumab Janus Kinase In… Tofacitinib Upadacitinib Arthritis Arthritis, Rheu… Rheumatoid Arth… | Decision of the local healthcare authority - | |||
| NCT04602065 Details | 2023-03-15 Interventional | 1/2 | 9 | Antibodies Antibodies, Bis… Lymphoma Lymphoma, Extra… Lymphoma, T-Cel… Lymphoma, T-Cel… Extranodal NK/T… | Due to the company's development strategy adjustment, Innovent Biologics has decided not to
continue this study after consultation with investigators. - |